Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Conditions: Triple Negative Breast Cancer Interventions: Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Docetaxel; Drug: Carboplatin; Procedure: Breast Surgery; Drug: Capecitabine Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Conditions: Locally Advanced Rectal Cancer; Neoadjuvant Therapy Interventions: Drug: PD-1 antibody; Drug: Capecitabine; Radiation: Short-course radiotherapy Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Conditions: Colorectal Cancer Metastatic Interventions: Drug: Adebrelimab; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab Sponsors: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Efficacy; Toxicity Interventions: Drug: Induction Immunotherapy-Toripalimab; Drug: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin; Radiation: Radiotherapy; Drug: Apatinib; Drug: Capecitabine Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Conditions: Triple Negative Breast Cancer Interventions: Drug: SKB264; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Capecitabine; Drug: Eribulin; Drug: Carboplatin Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma; High-Risk Cancer; Maintenance Therapy Interventions: Drug: Maintenance Therapy with Toripalimab and Capecitabine; Drug: Maintenance Therapy with Capecitabine Sponsors: Jiangxi Provincial Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Conditions: Breast Cancer Interventions: Drug: Cisplatin injection and gemcitabine; Drug: Capecitabine tablets Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Conditions: Breast Cancer; Refractory Breast Carcinoma Interventions: Other: Organoid-guided personalized treatment; Drug: Gemcitabine; Drug: Capecitabine; Drug: Vinorelbine; Drug: Eribulin Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Conditions: Rectal Adenocarcinoma Interventions: Drug: Adebrelimab; Drug: Oxaliplatin; Drug: Capecitabine; Radiation: Short-course Radiation; Procedure: Biopsy Sponsors: Sir Run Run Shaw Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: Anti-PD1 antibody, nimotuzumab and capecitabine Sponsors: Jiangxi Provincial Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Fluzoparib; Drug: Apatinib Mesylate; Drug: Capecitabine tablets; Drug: Vinorelbine Tartrate Oral; Drug: Eribulin mesylate injection; Drug: Gemcitabine Hydrochloride; Drug: Paclitaxel-albumin Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-na ïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Conditions: Gastric Cancer Interventions: Drug: ONO-4578; Drug: Oxaliplatin; Drug: Capecitabine; Drug: S-1; Drug: Nivolumab; Drug: Placebo Sponsors: Ono Pharmaceutical Co. Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Conditions: Breast Cancer Interventions: Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-NeoB; Drug: Capecitabine Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Conditions: Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Interventions: Drug: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection; Drug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
The Therapeutic Effect of Different Doses of Capecitabine
Conditions: Capecitabine Interventions: Drug: capecitabine Sponsors: Jingjiang People ' s Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
